asp42001
4 años hace
BDX & Louis A. Hoch Jt. Patent Protection
BDX & "LA" Hoch share a patent, covering needles & needle devices.
Used needles during a world-wide pandemic, will have to be destroyed, or they'll end-up in Oceans !
Louis A. Hoch, CEO of USIO, created "Appointment Guardian," that's currently in-active. A (n) AG is needed to help coordinate the disposal of HazMat material, during the world-wide spread of COVID-19.
It would behoove BDX & USIO to get involved with the "safe" disposal of COVID-19 hazardous material. USIO works "smack-dab" in the middle where billing, payments, records, record keeping and security cross-paths.
BDX & Healthcare HazMat Team fUSIOn needed. Train loads of used needles and other materials must be disposed of properly. For this and other reasons I alerted on BDX & USIO stock.
(: }}} ---- Dial-Up the Haz-Mat Team's Appointment Guardian, win the War!
DEAL!
asp42001 & Beyond!
whytestocks
6 años hace
News: $BDX BD Announces Preliminary Results For 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance
FRANKLIN LAKES, N.J. , Jan. 17, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported preliminary financial results for the first fiscal quarter ended December 31, 2018. Subject to the completion...
Read the whole news https://marketwirenews.com/news-releases/bd-announces-preliminary-results-for-2019-first-fiscal-quarter-reaffirms-fiscal-2019-guidance-6995626.html
TREND1
8 años hace
FRANKLIN LAKES, N.J., Sept. 21, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of its next generation wireless rapid diagnostic system for detection of influenza A and B, respiratory syncytial virus (RSV) and group A strep, with new traceability and secure patient health record documentation features and functionality.
Enterprising Investor
9 años hace
Becton Sued For Squeezing Out Rivals With Safer Syringes (7/17/15)
By Kelly Knaub
Law360, New York (July 17, 2015, 7:57 PM ET) -- Southeast Georgia Health System hit Becton Dickinson and Co. with a putative class action in Georgia federal court Friday, accusing the medical technology company of pushing competitors making safer needles out of the hypodermic syringes market.
The hospital alleges that despite federal law mandating practices to reduce dangerous needlestick injuries from conventional syringes since 2001 — injuries nurses experience more than 600,000 times annually, the suit says — New Jersey-based BD has slowly made only minor and ineffective changes to its conventional syringes, failing to reduce needlesticks and in some cases dramatically increasing them.
Southeast Georgia says that instead of competing and improving upon the technology put forth by Retractable Technologies Inc., which sells patented syringes that reduce needlesticks to a minimum and have been given the highest safety rating by a prominent testing laboratory, BD has suppressed competition and maintained its monopoly through a variety of schemes.
“Rather than compete, and meet and improve upon Retractable’s innovation on the merits using its vast resources to protect the national health, Becton has taken the low road of the repetitive antitrust scofflaw,” the hospital says.
BD is suppressing competition through, for example, exclusionary bundled rebates that foreclose acute care providers from effective competitive access to safer syringes; penalty contracts and sole-source contracts that achieve the same end; theft of Retractable’s innovative technology to use it against Retractable and greatly impede its market entry; six years of competitive deception and false advertising; and the elimination of a significant safety rival by acquisition, according to the suit.
BD is also using many of the same schemes to obtain and maintain a monopoly in the market for the sale of IV catheters to acute care providers, the complaint claims.
Southeast Georgia’s complaint brings one count of syringe monopolization and one count of IV catheter monopolization, both brought under Section 2 of the Sherman Act.
The hospital said it seeks to represent proposed classes of thousands of acute care providers purchasing syringes and IV catheters under cost-plus distribution contracts.
In August 2013, BD struck a $22 million settlement with hospitals and pharmacies whose class actions accused the company of stifling competition from other hypodermic product makers.
And earlier this year, Retractable claimed it deserved $5.65 million in prejudgment interest in a false advertising and antitrust suit it brought against BD — on top of the $340 million it won — but a Texas federal judge instead granted BD’s bid to vacate the prejudgment interest.
A BD representative did not immediately return a request for comment.
Southeast Georgia is represented by Wallace E. Harrell and Mark D. Johnson of Gilbert Harrell Sumerford & Martin PC and R. Stephen Berry of Berry Law PLLC.
Counsel information for Becton Dickinson was not immediately available.
The case is Glynn-Brunswick Hospital Authority et al. v. Becton Dickinson and Co., case number 2:15-cv-00091, in the U.S. District Court for the Southern District of Georgia.
http://www.law360.com/articles/680556/becton-sued-for-squeezing-out-rivals-with-safer-syringes
Enterprising Investor
10 años hace
Retractable Technologies, Inc. Announces Amended Final Judgment and Notice of Appeal (4/27/15)
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE MKT: RVP) (“RTI”) announced that on April 23, 2015, the United States District Court for the Eastern District of Texas, Marshall Division, entered an Amended Final Judgment in RTI’s suit against Becton, Dickinson and Company (“BD”) for antitrust and other claims.
The Amended Final Judgment states:
1. BD attempted to monopolize the safety syringe market.
2. BD committed false advertising under the Lanham Act.
3. RTI recovers from BD $340,524,042.00.
4. RTI recovers from BD its attorneys’ fees in the amount of $11,722,823.20.
5. RTI is further awarded post-judgment interest and costs.
6. The Court GRANTS injunctive relief consistent with its prior orders.
On April 24, 2015, BD filed a Notice of Appeal announcing its appeal of the Amended Final Judgment and various other post-trial and post judgment orders to the United States Court of Appeals for the Fifth Circuit.
RTI manufactures and markets VanishPoint® and Patient Safe® safety medical products. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. RTI’s products are distributed by various specialty and general line distributors.
For more information on RTI, visit our website at www.vanishpoint.com.
http://www.businesswire.com/news/home/20150427006168/en/Retractable-Technologies-Announces-Amended-Final-Judgment-Notice#.VT6FeIktGUk
Enterprising Investor
10 años hace
Retractable Technologies, Inc. Announces U.S. Supreme Court Decision – Denial of Writ of Certiorari (4/21/15)
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE MKT: RVP) announced that on April 20, 2015, the Supreme Court of the United States denied the petition for a writ of certiorari by Becton, Dickinson and Company (“BD”) relating to its Rule 60(b) motion in the portion of Retractable’s case against BD addressing patent infringement claims.
The patent claims were severed from Retractable’s other claims against BD in 2008. The other portion of the case in which the District Court granted Retractable a final judgment for $352 million plus other relief is not directly affected by the recent Supreme Court ruling.
Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. Retractable's products are distributed by various specialty and general line distributors.
For more information on Retractable, visit our website at www.vanishpoint.com.
http://www.businesswire.com/news/home/20150421006314/en/Retractable-Technologies-Announces-U.S.-Supreme-Court-Decision#.VTZ0g4ktGUk
BikerBob
10 años hace
BD Board Declares Dividend
4:05p ET January 27, 2015 (PR NewsWire) Print
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 60 cents per common share, payable on March 31, 2015 to holders of record on March 10, 2015. The indicated annual dividend rate is $2.40 per share.
About BDBD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We have more than 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.
Contact:Ed Cook, Corporate Communications - 201-847-7176Monique N. Dolecki, Investor Relations - 201-847-5378
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bd-board-declares-dividend-300026217.html
SOURCE BD (Becton, Dickinson and Company)
56Chevy
10 años hace
FYI -
Court of Appeals Order – Retractable Technologies, Inc., et al., v. Becton, Dickinson and Co (2/05/15)
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE MKT: RVP) (“RTI”) announced today that on February 3, 2015 the United States Court of Appeals for the Fifth Circuit issued an order which denied Becton, Dickinson and Co.’s (“BD”) motion for stay of injunction pending appeal.
In previous press releases, RTI has reiterated the requirements of the injunction at issue, which, among other things, require BD to notify its customers and others that it wrongfully distributed false and misleading advertisements. Except to the extent stayed by the District Court’s January 14 order, the notices required by the injunction must be sent by BD no later than February 14, 2015. BD had requested a stay of the injunction pending appeal. The Fifth Circuit opinion did not expand on its reasoning for denying BD’s motion.
Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. Retractable's products are distributed by various specialty and general line distributors.
For more information on Retractable, visit our website at www.vanishpoint.com.
http://www.businesswire.com/news/home/20150205005248/en/Court-Appeals-Order-%E2%80%93-Retractable-Technologies-al.#.VNOEg4ktGUk
*This lawsuit can't be good for BDX...expect fallout by mid-month if not sooner.
Marker;
Becton, Dickinson An (BDX)
$145.29 up 5.37 (3.84%)
Volume: 1,785,511
investora2z
12 años hace
You can't argue with stocks which make historic highs all the time. Several pharma company stocks have recently been in the habit of doing so. BDX is also doing very well for investors, and has delivered good returns over past several years. The stock appreciated 32% during the last year, and is only ~6% below its all time high of ~$102 made recently. The dividend history of the stock is also great, with a good 2% yield over the past 5 years at a reasonable 25% payout. Fundamentally, the revenue growth has been very good over the past few years. The net income, however, has remained static and shown some declines recently. The operating margins are around 20%. Despite the great growth, the trailing P/E is less than 13 which indicates reasonable valuations. Future growth in fundamentals will be the key to continued appreciation of the stock. But the forward P/E and the high PEG ratio indicates that the growth expectations in the medium term are not very high. BDX is basically relying on new product launches, licensing and network expansion etc. for future growth. The new products will help it bolster growth and further build its IPR portfolio which is always so crucial. A smaller medical device company, PLC Systems (PLCSF) recently obtained several patents for its single proprietary product RenalGuard which is used for contrast induced neuropathy. Patents are important assets for the medical device companies, and can help in increasing sales and generating regular stream of licensing revenues. BDX's new products like the cytometer and the injection for diabetics are also expected to do well in the market. Innovation is the key to long term success. If the markets hold, then one can expect reasonable returns. Slippages can lead to some profit booking so the fundamentals have to keep pace.
auroradude
14 años hace
Released today -
Analyst Research on J&J, Fiserv, Sanofi-Aventis and Becton Dickenson -- Buffett Raises His Stake
Becton Dickinson (NYSE:BDX)
Intraday Stock Chart
Today : Thursday 19 August 2010
The Bedford Report is pleased to announce that its latest Market Update analyzing recent news and events on Johnson & Johnson (NYSE: JNJ), Fiserv, Inc. (NASDAQ: FISV), Sanofi-Aventis (NYSE: SNY) and Becton Dickenson & Co. (NYSE: BDX) has been released. Sign up today at www.bedfordreport.com to access our complimentary analyst reports.
Recently Warren Buffett and Berkshire Hathaway bet big on healthcare. They raised their stake in Johnson & Johnson by close to 73% in what's considered a classic Buffett "value play." Berkshire also added to its stake in the medical device maker Becton Dickenson and drugmaker Sanofi-Aventis. To learn more about Warren Buffett's reasoning behind these big healthcare bets, we encourage you to sign up at www.bedfordreport.com.
Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
EarningsCentral
2 meses hace
ValueInvestor15
8 años hace
ernie44
11 años hace
Penny Roger$
13 años hace
Hot Features
Premium
